Development of robust iPSC-based α-Synuclein, Tau and TDP-43 aggregation models for drug discovery

Jessica Koepke, Isabel Onofre, Carola van Berkel, Tatiana Wust, Leo Smit, Joyson Dcosta, Chiara Formica, Kimberley Riegman, Benoit Samson-Couterie and Shushant Jain
Ncardia Services BV Leiden, The Netherlands, support@ncardia.com, www.ncardia.com

Disclosures: None

Background

Proteinopathies are diseases caused by protein misfolding and self-aggregation, which leads to altered neuronal function and neurodegeneration. Examples of proteinopathies include Parkinson's Disease (PD), Alzheimer's Disease (AD) and Amyotrophic lateral sclerosis (ALS).
Proteinopathies are complex diseases difficult to model in vitro and in vivo. Many therapies that showed promise in animal studies have failed in human clinical trials, emphasizing a translation gap in the drug discovery process.
Developing human physiologically relevant disease models is of high importance to identify and validate drugs therapeutic potential with higher confidence of clinical success. Human induced pluripotent stem cells (hiPSCs) have the potential to be differentiated into any cell type, retain patient-specific genetic backgrounds, mimic clinically-relevant human (patho-)physiology and respond appropriately to candidate therapeutics. These characteristics make hiPSCs an excellent tool for drug discovery.

In this study, Ncardia developed three in vitro assays based on hiPSC-derived neurons to model the aggregation of α-synuclein, Tau and TDP-43 – key hallmarks for diseases like Parkinson's, Alzheimer's or Amyotrophic Lateral Sclerosis.

Figure A shows the experimental set-up, timeline and endpoints of Ncardia's AD, PD and ALS pathology model. Assays in purple and in green can be combined and multiplexed





Postulated model for protein aggregation mechanisms in neurodegenerative diseases

- Misfolding of specific characteristic disease related proteins is suggested to be linked to disease progression, resulting in aggregation and fibril formation of these proteins.
- One disease protein aggregates and loses its function or additionally shows a toxic gain of function.

Bahareh Eftekharzadeh, Bradley T. Hyman, Susanne Wegmann
Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases, Mechanisms of Ageing and Development, Volume 156, 2016, Pages 1-13, ISSN 0047-6374, https://doi.org/10.1016/j.mad.2016.03.001.

1. Aggregation of α-synuclein and phenotypic rescue



Figure A, B and C Fluorescent images of cells, acquired with a 20x objective and stained for DAPI (blue), SNCA (green), MAP2 (grey) and phospho α-syn pS129 (red). **Figure B** shows vehicle-treated (left) and inhibitor of protein degradation-treated cells at 0.1 µM (right). **Figure C** vehicle-treated (left) and lysosomal activator-treated cells.



Figure D Quantification of normalized puncta and phosphorylated puncta counts of cells without PFFs (purple) compared to cells treated with PFFs (turquoise), expressed as % to cells with PFFs set to 100%.



Figure E Quantification of the normalized parameters (α-syn/phospho α-syn ratio and α-syn area) of cells treated with increasing concentrations of MG132 [µM], expressed as % to cells with PFFs set to 100%.



Figure F Quantification of the normalized parameters (α-syn/phospho α-syn ratio, and α-syn area) of cells treated with a lysosomal activator [µM], expressed as % to cells with PFFs set to 100%.

Plotted values are averages ±SD. Statistical significance calculated with unpaired t-test * p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0000.1

Activation of protein degradation significantly decreased the number and area of α-syn aggregates in a concentration-dependent manner

2. Electrophysiological dysfunction in a model of PD



Figure A Representative raster plots of MEA (action potential activity) after treatment with α-syn monomers or PFF for 7 days and compound rescuing neurotoxic phenotype (y-axis: electrodes, x-axis: 5 min recording time).



Figure B Quantification of the normalized parameters (weighted mean firing and number of bursts) of cells treated with α- sun monomers or PFFs in combination with compound X , expressed as % vehicle condition set to 100%.

Treatment of Ncyte CNS with α-syn monomers or pre-formed fibrils (PFF) disturbed Ncyte CNS electrical activity

3. Aggregation of Tau and pTau - Quantifying aggregation



Figure A Tau overexpression by transduction in combination with chronic treatment with Tau PFFs (condition transduced +PFF) showed a notable increase in misfolded Tau (MC-1 in purple) and pTau (green) signals, resembling Tau pathology observed in Alzheimer's disease (magnification 20x)



Figure B Fixation of neurons with methanol, removes the phosphorylated Tau (green) and MC-1 positive Tau (purple) but in condition transduced +PFFs, Tau signal (orange) is still present, indicating the formation of insoluble tau aggregates (magnification 20x).



Figure C Quantification of the normalized parameters (intensity and puncta counts of MC-1 and pTau) of untransduced cells (UNT in purple) compared to cells transduced and treated with PFFs (TR+ PFFs in turquoise), expressed as % to condition UNT set to 0%.

Plotted values are averages ±SD. Statistical significance calculated with unpaired t-test * p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0000.1

Overexpression of TAU combined with chronic exposure to PFFs induced an Alzheimer's disease phenotype

4. Mis-localization and aggregation of TDP-43 and downregulation STMN2



Figure A Fluorescent images of motor neurons expressing wild type and mutated TDP-43 (M337V mutation), treated with vehicle or stressor and stained for TD43. Cytoplasmic staining of TDP-43 can be observed in the mutant neurons as well as in all neurons treated with the stressor (magnification 40x, scale bar 100 µm).

Figure B Quantification of the normalized parameter (ratio of cytoplasmic/nuclear TDP43) of wild type and mutated TDP-43 (M337V mutation) motor neurons, compared to wild type neurons (in purple) and expressed as % to condition set to 100%.

Figure C Quantification of the normalised parameter (TDP-43 aggregation) by HTRF of wild type and mutated TDP-43 (M337V mutation) motor neurons, compared to wild type neurons (in purple) and expressed as % to condition set to 100%. The mutant motor neurons show a suggestive increase in TDP-43 aggregation but the addition of a stressor, consistently and robustly increases TDP-43 aggregation.

* iCell® Motor Neurons 01279 from FUJIFILM Cellular Dynamics, Inc.



Figure D Fluorescent images of motor neurons expressing wild type and mutated TDP-43 (M337V mutation), treated with vehicle or stressor and stained for Sthatmin2 (yellow) and DAPI (blue). Reduction of neurite staining of Sthatmin2 can be observed in motor neurons treated with the stressor (magnification 40x).



Figure E Quantification of the normalized parameter (Sthatmin-2 puncta in neurites) of wild type and mutated TDP- 43 (M337V mutation) motor neurons, compared to wild type neurons (in purple) and expressed as % to condition set to 100%.



Figure F Quantification of RNA levels of STMN2 and truncated STMN2 by qPCR.
Data was normalized to wild type neurons (in purple)
Upon treatment with the stressor, STMN2 levels significantly decreased while there was a significant increase in truncated STMN2 levels.

Plotted values are averages ±SD. Statistical significance calculated with two-way ANOVA * p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0000.1
For the outlined studies, motor neurons from Fujifilm were used.

Motor neurons chronically treated with a stressor show mis-localization of TDP-43 to the cytoplasm, aggregation of TDP-43, reduction of STMN2 and appearance of the truncated variant

Conclusions

- Neuronal co-cultures were used to quantify disease relevant phenotypes for α-synuclein or TAU aggregation as well as the formation intermediate phosphorylated species after treatment with α-synuclein and Tau recombinant preformed fibrils (PFFs) using a high content imaging platform. Inhibitors and activators of protein degradation produced the expected changes in protein aggregation in a concentration-dependent manner. Stressor-treated mutant and wild type iPSC-derived motor neurons (hiPSC-MN) showed disease-specific mis-localization of TDP-43 to the cytoplasm, aggregation of TDP-43, reduction of STMN2 and appearance of the truncated variant.
- We have established a suite of robust, clinically relevant in vitro assays (Z-factor >0.5) for the aggregation of α-synuclein, Tau and TDP-43 using human iPSC-derived neuronal subtypes. These assays are performed in a scalable wellplate format and are fully automated to support drug developers at any stage of their discovery process.
- We successfully modelled and evaluated disease-linked phenotypes relevant to AD, PD and ALS, among other neurodegenerative disorders, using complimentary assays. Altogether, offering the opportunity to gain a holistic understanding of the efficacy of therapeutics targeting aggregation.

Scan to download the poster

Questions? Contact us at:
support@ncardia.com
www.ncardia.com